Image

Lung Nodule Detection Using Ultra-long FOV PET/CT

Lung Nodule Detection Using Ultra-long FOV PET/CT

Recruiting
18 years and older
All
Phase 4

Powered by AI

Overview

Indeterminate lung nodules (6-15mm) are frequent findings in patients undergoing chest CT scanning, but adequate follow-up imaging is currently not in place to facilitate early detection, diagnosis and decision making regarding treatment.

The introduction of long Field-Of-View PET/CT scanners could make a difference in this matter due to the substantial increase in sensitivity allowing optimal image quality. Whether this new technology could provide improved detection and follow-up of indeterminate lung nodules is what we aim to explore in this study.

Description

Indeterminate lung nodules (6-15 mm) are frequent findings in patients undergoing chest Computed Tomography (CT). In the large randomized controlled Dutch-Belgian lung cancer screening trial NELSON, overall, 9.2% of the screened participants had an initially indeterminate CT scan. To decrease mortality from lung cancer, early identification of malignant lesions among the many lung nodules is crucial. The probability of malignancy depends on size and other factors. It is difficult to determine whether a nodule is malignant on size alone. For further differentiation of a lung nodule, usually, repeated chest CT scanning is performed at 3-6 months up to 2 years to assess nodule growth, and/or 2-deoxy-2-[fluorine-18) fluoro-D-glucose (18F-FDG) Positron Emission Tomography (PET)/CT to evaluate metabolic activity. However, repetitive CT scans are not favoured because of radiation exposure, patiƫnt anxiety, and potential delay in cancer diagnosis. Furthermore, 18F-FDG PET/CT has thus far insufficiƫnt sensitivity for detection and characterization of small (in particular < 1 cm) lung nodules, meaning that a negative result does not rule out the presence of cancer, which thus usually requires further follow-up CT scans. Improvement in work-up of indeterminate lung nodules is urgently needed, in particular with the expected introduction of lung cancer screening in the coming years.

In this study, the aim is to derive optimal imaging procedures and to assess the technical performance of the Vision Quadra PET/CT system concerning its feasibility to detect indeterminate lung nodules. Furthermore, this study aims to preliminary explore the sensitivity, specificity, and accuracy of the characterisation of lung nodules using the Vision Quadra PET/CT.

After enrolment, patients will receive a Standard 3 MBq/kg injection of 18F-FDG and undergo whole-body dynamic PET/CT acquisition at 30-60 min post-injection (pi), followed by a 10 min whole-body list-mode PET/CT acquisition. Subsequently, patients will be asked to hold their breath for 15 seconds to assess the added value of a single fast deep-inspiration breath-hold acquisition.

At 120 min pi a second 10 min whole-body list-mode PET/CT will be acquired to potentially further differentiate between inflammation and malignancy.

The list-mode acquisitions can be reprocessed retrospectively with less counts to produce images representing scans collected with lower activity administration or shorter scan times (e.g., a 1 min instead of 10 min PET scan is equivalent to 10% of the injected activity at scan start). Quantitative image analysis results will be correlated with pathology (benign or malignant) of the lung lesion, and results of a previously performed routine-care 18F-FDG PET/CT and CT chest.

Eligibility

Inclusion Criteria:

  • able to give informed consent
  • signed informed consent
  • confirmed indeterminate lung nodule(s) of 6-15 mm in size on CT chest imaging
  • routine 18F-FDG PET/CT performed
  • scheduled for biopsy or resection of the lung nodules

Exclusion Criteria:

  • claustrophobia
  • pregnant or breastfeeding
  • interval of at least 2 weeks between PET scan and last date of systemic anti-cancer therapy to reduce false-negative uptake in lesions
  • radiation therapy of the target lung nodule(s)
  • uncontrolled diabetes mellitus
  • any medical condition potentially hampering conduction of the trial

Study details
    Lung Cancer

NCT05463913

University Medical Center Groningen

14 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.